The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced ...

A new study reveals disappointing results on the potential of GLP-1 drugs like Ozempic to treat Parkinson's disease. Despite ...

A compound that showed early promise in the treatment of Parkinson's disease in fruit flies has also shown neuroprotective ...

Nicole LaBolle initially dismissed her shaking as something fairly common before facing a Parkinson's diagnosis at 28 ...

The U.S. Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only ...

The FDA has approved the first and only subcutaneous apomorphine infusion device, apomorphine hydrochloride injection (Onapgo ...

Parkinson’s disease is a brain disorder that affects movement, making everyday tasks difficult for nearly one million people ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

GOTHENBURG, SE / ACCESS Newswire / February 7, 2025 /IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, February ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

While dopamine-based medications are effective early in treatment, they often lead to significant and unpleasant side effects over time. Scientists have been searching for a cure for Parkinson’s ...

The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat ...